



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

March 5, 2020

Via E-mail

Matthew Kapusta  
Chief Executive Officer  
UniQure N. V.  
Paasheuvelweg 25a  
1105 BP Amsterdam, The Netherlands

**Re: UniQure N. V.**  
**Form 10-Q for the quarterly period ended September 30, 2019**  
**Exhibit No. 10.4 - Amended and Restated Collaboration Agreement by and between**  
**4D Molecular Therapeutics, Inc and uniQure biopharma B.V., dated August 6, 2019**  
**Exhibit No. 10.5 - Collaboration and License Agreement by and between 4D**  
**Molecular Therapeutics, Inc and uniQure biopharma B.V., dated August 6, 2019**  
**Filed October 28, 2019**  
**File No. 001-36294**

Dear Mr. Kapusta:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance